197 related articles for article (PubMed ID: 30692637)
1. VPAC1 couples with TRPV4 channel to promote calcium-dependent gastric cancer progression via a novel autocrine mechanism.
Tang B; Wu J; Zhu MX; Sun X; Liu J; Xie R; Dong TX; Xiao Y; Carethers JM; Yang S; Dong H
Oncogene; 2019 May; 38(20):3946-3961. PubMed ID: 30692637
[TBL] [Abstract][Full Text] [Related]
2. Expression and localization of VPAC1, the major receptor of vasoactive intestinal peptide along the length of the intestine.
Jayawardena D; Guzman G; Gill RK; Alrefai WA; Onyuksel H; Dudeja PK
Am J Physiol Gastrointest Liver Physiol; 2017 Jul; 313(1):G16-G25. PubMed ID: 28385693
[TBL] [Abstract][Full Text] [Related]
3. Calcium Promotes Human Gastric Cancer via a Novel Coupling of Calcium-Sensing Receptor and TRPV4 Channel.
Xie R; Xu J; Xiao Y; Wu J; Wan H; Tang B; Liu J; Fan Y; Wang S; Wu Y; Dong TX; Zhu MX; Carethers JM; Dong H; Yang S
Cancer Res; 2017 Dec; 77(23):6499-6512. PubMed ID: 28951460
[TBL] [Abstract][Full Text] [Related]
4. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production.
Kojima M; Ito T; Oono T; Hisano T; Igarashi H; Arita Y; Kawabe K; Coy DH; Jensen RT; Nawata H
Pancreas; 2005 Jan; 30(1):62-70. PubMed ID: 15632701
[TBL] [Abstract][Full Text] [Related]
5. VPAC1 receptors regulate intestinal secretion and muscle contractility by activating cholinergic neurons in guinea pig jejunum.
Fung C; Unterweger P; Parry LJ; Bornstein JC; Foong JP
Am J Physiol Gastrointest Liver Physiol; 2014 May; 306(9):G748-58. PubMed ID: 24578344
[TBL] [Abstract][Full Text] [Related]
6. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis.
Yadav M; Huang MC; Goetzl EJ
Cell Immunol; 2011; 267(2):124-32. PubMed ID: 21295288
[TBL] [Abstract][Full Text] [Related]
7. The role of vasoactive intestinal peptide (VIP) in megakaryocyte proliferation.
Nam C; Case AJ; Hostager BS; O'Dorisio MS
J Mol Neurosci; 2009 Feb; 37(2):160-7. PubMed ID: 18663606
[TBL] [Abstract][Full Text] [Related]
8. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells.
Delgado M; Robledo G; Rueda B; Varela N; O'Valle F; Hernandez-Cortes P; Caro M; Orozco G; Gonzalez-Rey E; Martin J
Arthritis Rheum; 2008 Apr; 58(4):1010-9. PubMed ID: 18383379
[TBL] [Abstract][Full Text] [Related]
9. Stimulatory effect of pituitary adenylate cyclase-activating polypeptide 6-38, M65 and vasoactive intestinal polypeptide 6-28 on trigeminal sensory neurons.
Sághy É; Payrits M; Helyes Z; Reglődi D; Bánki E; Tóth G; Couvineau A; Szőke É
Neuroscience; 2015 Nov; 308():144-56. PubMed ID: 26321242
[TBL] [Abstract][Full Text] [Related]
10. Vasoactive intestinal peptide (VIP) stimulates cortisol secretion from the H295 human adrenocortical tumour cell line via VPAC1 receptors.
Nicol MR; Cobb VJ; Williams BC; Morley SD; Walker SW; Mason JI
J Mol Endocrinol; 2004 Jun; 32(3):869-77. PubMed ID: 15171718
[TBL] [Abstract][Full Text] [Related]
11. Screening of a specific peptide binding to VPAC1 receptor from a phage display peptide library.
Tang B; Li Z; Huang D; Zheng L; Li Q
PLoS One; 2013; 8(1):e54264. PubMed ID: 23365656
[TBL] [Abstract][Full Text] [Related]
12. Epithelial expression of vasoactive intestinal peptide in ulcerative colitis: down-regulation in markedly inflamed colon.
Jönsson M; Norrgård O; Forsgren S
Dig Dis Sci; 2012 Feb; 57(2):303-10. PubMed ID: 22143367
[TBL] [Abstract][Full Text] [Related]
13. Endogenous inhibition of hippocampal LTD and depotentiation by vasoactive intestinal peptide VPAC1 receptors.
Cunha-Reis D; Aidil-Carvalho Mde F; Ribeiro JA
Hippocampus; 2014 Nov; 24(11):1353-63. PubMed ID: 24935659
[TBL] [Abstract][Full Text] [Related]
14. Suppression of tumorigenicity in neuroblastoma cells by upregulation of human vasoactive intestinal peptide receptor type 1.
Balster DA; O'Dorisio MS; Albers AR; Park SK; Qualman SJ
Regul Pept; 2002 Nov; 109(1-3):155-65. PubMed ID: 12409228
[TBL] [Abstract][Full Text] [Related]
15. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
Cunha-Reis D; Ribeiro JA; Sebastião AM
Brain Res; 2005 Jul; 1049(1):52-60. PubMed ID: 15935995
[TBL] [Abstract][Full Text] [Related]
16. Effect of vasoactive intestinal peptide on gastric adenocarcinoma.
Li GH; Qian W; Song GQ; Hou XH
J Gastroenterol Hepatol; 2007 Aug; 22(8):1328-35. PubMed ID: 17559364
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
[TBL] [Abstract][Full Text] [Related]
18. Generation of PEGylated VPAC1-selective antagonists that inhibit proliferation of a lung cancer cell line.
Pan CQ; Hamren S; Roczniak S; Tom I; DeRome M
Peptides; 2008 Mar; 29(3):479-86. PubMed ID: 17942192
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance.
Fernández-Martínez AB; Carmena MJ; Arenas MI; Bajo AM; Prieto JC; Sánchez-Chapado M
Histol Histopathol; 2012 Aug; 27(8):1093-101. PubMed ID: 22763881
[TBL] [Abstract][Full Text] [Related]
20. Gene expression of vasoactive intestinal peptide receptors in human lung cancer.
Szilasi M; Buglyo A; Treszl A; Kiss L; Schally AV; Halmos G
Int J Oncol; 2011 Oct; 39(4):1019-24. PubMed ID: 21769421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
